Vireo Growth VREOF
OTC VREOF
$10.97 -0.01 (-0.09%)
At close: Aug 19, 2026 · 3:35 PM UTC

Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)

Vireo Growth (VREOF) posted Total Non-Current Liabilities of $604.7 million for Q1 2026, up 19.08% sequentially from $507.8 million in Q4 2025, and up 166.89% YoY from $226.6 million in Q1 2025.

Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Vireo Growth has reported Total Non-Current Liabilities for 6 years, with the latest figure at $604.7 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 166.89% year-over-year to $604.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $604.7 million (up 166.89% YoY) and the FY2025 annual result came in at $507.8 million, up 127.41% from the prior year.
  • Total Non-Current Liabilities rose to $604.7 million in Q1 2026 per VREOF's latest filing, from $507.8 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $604.7 million in Q1 2026 and troughed at $155.7 million in Q4 2022.
  • A 5-year average of $286.3 million and a median of $217.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities climbed 6.14% in 2025, then jumped 166.89% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $155.7 million in 2022, then grew by 27.92% to $199.2 million in 2023, then rose by 12.11% to $223.3 million in 2024, then surged by 127.41% to $507.8 million in 2025, then rose by 19.08% to $604.7 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $604.7 million, $507.8 million, and $431.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 43.28 Bn 39.62 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.79 Bn 30.11 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.69 Bn 22.89 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.25 Bn 19.58 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.87 Bn 11.34 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - 334.00 Mn
10 Vireo Growth 487.39 Mn 345.09 Mn 95.30 Mn 830.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 604.70 Mn
Dec 31, 2025 507.80 Mn
Sep 30, 2025 431.51 Mn
Jun 30, 2025 380.13 Mn
Mar 31, 2025 226.57 Mn
Dec 31, 2024 223.30 Mn
Sep 30, 2024 204.66 Mn
Jun 30, 2024 217.04 Mn
Mar 31, 2024 213.46 Mn
Dec 31, 2023 199.19 Mn
Sep 30, 2023 184.29 Mn
Jun 30, 2023 173.66 Mn
Dec 31, 2022 155.71 Mn
Sep 30, 2021 110.17 Mn
Jun 30, 2021 52.73 Mn
Mar 31, 2021 58.01 Mn